基于DoE开发和优化含有比马托普罗斯特的离子敏感in situ纳米乳液,用于持续的眼部输送
Monika Singh1, Meena Devi1, Rahul Pratap Singh1
1Department of Pharmaceutical Science, School of Healthcare and Allied Science, GD Goenka University, Gurugram, Haryana, India.
International journal of biological macromolecules
|September 20, 2025
概括
这项研究开发了一种用于治疗青光眼的新型比马托普罗斯特纳米乳液 (NEG),提供持续的药物释放和减少副作用. 新配方有效降低眼内压力 (IOP),并改善与传统眼药相比,眼睛的舒适度.
科学领域:
- 眼科和制药科学 眼科和制药科学
- 药物输送系统 药物输送系统
- 纳米技术在医学中的应用
背景情况:
- 青光眼的治疗依赖于每日降低眼内压力 (IOP) 的眼滴.
- 比马托普罗斯特是一种前列腺素类似物,是治疗青光瘤和眼睛高血压的常见治疗方法.
研究的目的:
- 制定和评估一款用于增强眼部药物递送 (ODD) 的新型本位纳米乳液 (NEG) 的比马托普罗斯特.
主要方法:
- 通过高压均质化制备纳米乳液,使用比马托普罗斯特,氨酸,藻类油,大豆莱西丁和tween 40.
- 设计质量 (QbD) 用于配方优化,然后进行表征 (Zeta大小,潜力,PDI,形态).
- 用于in situ凝的凝;纳米乳液 (NEG) 评估了物理,化学和释放性质;针对IOP,干眼和高血压进行的药理学研究.
主要成果:
- 优化的纳米乳液呈现出有利的粒子大小 (38.87 nm),Zeta潜力 (34.3 mV) 和PDI (0.282).
- 开发的NEG证明了sol-gel过渡,高药物含量 (99.76%),持续的体外药物释放,稳定性和无菌性.
- 药理动力学研究表明,显著的IOP降低和缓解干眼和结膜性高血症.
结论:
- 新型比马托普罗斯特NEG提供了长时间的眼部停留和持续释放,为传统眼药提供了有竞争力的替代品.
- 该配方富含omega-3脂肪酸和氨酸 (HA),可提供卓越的玻璃眼治疗,并减少相关药物不良反应 (ADRs).
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...